期刊
IMMUNOTHERAPY
卷 3, 期 10, 页码 1265-1274出版社
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.11.113
关键词
cancer; chronic inflammation infection; immunotherapy; metastatic renal cell carcinoma; sunitinib; wound healing
类别
资金
- NIH [P01 CA100327, R01 CA114071, R01 CA140375, P50 CA121973]
- University of Pittsburgh [P30 CA047904]
- American Cancer Society [PF-11-151-01-LIB]
Acute inflammatory reactions benefit the host by supporting the effective clearance of pathogens and fostering wound healing, in addition to other self-preservative processes. However, when the inflammatory program is not resolved, becoming chronic in nature, it creates an environment conducive to cancer development and progression. Therefore, minimizing exposure to risk factors that contribute to chronic inflammation and reconditioning the host towards a state of (at least locoregional) acute inflammation would meaningfully impact cancer incidence and its treatment, respectively. Regarding cancer therapy, combinational treatments that both disrupt chronic inflammation and install specific adaptive type I immunity are predicted to enhance quality of life and extend the overall survival of patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据